ELAC2
Basic information
Region (hg38): 17:12991612-13018065
Links
Phenotypes
GenCC
Source:
- combined oxidative phosphorylation defect type 17 (Supportive), mode of inheritance: AR
- combined oxidative phosphorylation defect type 17 (Strong), mode of inheritance: AR
- mitochondrial disease (Definitive), mode of inheritance: AR
- combined oxidative phosphorylation defect type 17 (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
| Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
|---|---|---|---|---|---|
| Combined oxidative phosphorylation deficiency 17 | AR | Biochemical; Cardiovascular | The condition can include severe cardiac sequelae, such as hypertrophic cardiomyopathy, and though some individuals have been described as not responding to therapy, others have been reported as benefitting from cardiac surveillance and early insitution of cardioprotective therapy and and biochemical dietary and medical treatment (eg, high-fat diet, coenzyme Q10, riboflavin, thiamine, and carnitine) | Biochemical; Cardiovascular; Neurologic | 23849775 |
ClinVar
This is a list of variants' phenotypes submitted to
- Combined_oxidative_phosphorylation_defect_type_17 (962 variants)
- not_provided (142 variants)
- Inborn_genetic_diseases (95 variants)
- Prostate_cancer,_hereditary,_2 (29 variants)
- not_specified (26 variants)
- ELAC2-related_disorder (19 variants)
- Ovarian_cancer (6 variants)
- Intellectual_disability (2 variants)
- Prostate_cancer,_hereditary,_2,_susceptibility_to (1 variants)
- Microcephaly (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ELAC2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000018127.7. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 249 | 258 | ||||
| missense | 11 | 372 | 15 | 403 | ||
| nonsense | 16 | 25 | ||||
| start loss | 0 | |||||
| frameshift | 22 | 28 | ||||
| splice donor/acceptor (+/-2bp) | 22 | 29 | ||||
| Total | 42 | 42 | 387 | 265 | 7 |
Highest pathogenic variant AF is 0.00089995144
GnomAD
Source:
| Gene | Type | Bio Type | Transcript | Coding Exons | Length |
|---|---|---|---|---|---|
| ELAC2 | protein_coding | protein_coding | ENST00000338034 | 24 | 25797 |
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
|---|---|---|---|---|---|---|
| 1.72e-20 | 0.0771 | 125450 | 1 | 297 | 125748 | 0.00119 |
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | -0.410 | 479 | 454 | 1.05 | 0.0000268 | 5359 |
| Missense in Polyphen | 164 | 163.82 | 1.0011 | 1918 | ||
| Synonymous | -2.25 | 219 | 180 | 1.21 | 0.0000114 | 1605 |
| Loss of Function | 1.30 | 36 | 45.5 | 0.792 | 0.00000236 | 523 |
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p |
|---|---|---|
| African & African-American | 0.0111 | 0.0111 |
| Ashkenazi Jewish | 0.00 | 0.00 |
| East Asian | 0.000491 | 0.000489 |
| Finnish | 0.000647 | 0.000647 |
| European (Non-Finnish) | 0.000619 | 0.000571 |
| Middle Eastern | 0.000491 | 0.000489 |
| South Asian | 0.000490 | 0.000490 |
| Other | 0.000823 | 0.000815 |
dbNSFP
Source:
- Function
- FUNCTION: Zinc phosphodiesterase, which displays mitochondrial tRNA 3'-processing endonuclease activity. Involved in tRNA maturation, by removing a 3'-trailer from precursor tRNA. {ECO:0000269|PubMed:21593607}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 17 (COXPD17) [MIM:615440]: An autosomal recessive disorder of mitochondrial dysfunction characterized by onset of severe hypertrophic cardiomyopathy in the first year of life. Other features include hypotonia, poor growth, lactic acidosis, and failure to thrive. The disorder may be fatal in early childhood. {ECO:0000269|PubMed:23849775}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- RNA transport - Homo sapiens (human);tRNA processing;Metabolism of RNA;tRNA processing in the nucleus
(Consensus)
Recessive Scores
- pRec
- 0.0979
Intolerance Scores
- loftool
- 0.929
- rvis_EVS
- -0.91
- rvis_percentile_EVS
- 10.12
Haploinsufficiency Scores
- pHI
- 0.0435
- hipred
- N
- hipred_score
- 0.231
- ghis
- 0.579
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.485
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Elac2
- Phenotype
- mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Gene ontology
- Biological process
- tRNA 3'-end processing;mitochondrial tRNA 3'-trailer cleavage, endonucleolytic;mitochondrial tRNA processing
- Cellular component
- nucleus;nucleoplasm;mitochondrion;mitochondrial matrix;mitochondrial nucleoid
- Molecular function
- RNA binding;endonuclease activity;tRNA-specific ribonuclease activity;metal ion binding